Nivolumab-induced peritonitis with peritoneal mesothelial hyperplasia mimicking metastatic mesothelioma.

Abstract

A 57-year-old man developed a mesothelial proliferation in the peritoneum, several months after he was diagnosed with biopsy-proven epithelioid mesothelioma of the pleura and having undergone several treatments with checkpoint inhibitor immunotherapy. The differential diagnosis was metastatic mesothelioma from the lung primary, versus a reactive process. A diagnosis of atypical mesothelial proliferation was made. Follow-up CT showed no evidence of abdominal disease 5 months later. The complication of serositis following checkpoint inhibitor therapy is reviewed, as well as the differential diagnosis between reactive mesothelial hyperplasia and epithelioid mesothelioma.

• Authors: Allen Burke, Teklu Legesse
• Journal: AJSP: reviews & reports (AJSP Rev Rep) 2022 May-Jun Vol. 27 Issue 3 Pg. 98-102 ISSN: 2381-652X [Electronic] United States
• PMID: 35721693 (Publication Type: Journal Article)